A system and method for modulating stress granule assembly, utilizing a protein construct that has a cell penetrating protein fused to one or more proteins that can bind with an NTF2-like domain of a G3BP protein. By configuring the protein construct with an appropriate number of proteins that being with NTF2-like domains, stress granule assembly can be upregulated or downregulated as needed to treat patients.

Short peptides and peptidomimetics useful for treating Type 2 diabetes are provided, and methods for treating and/or preventing Type 2 diabetes and related conditions.

The present disclosure features useful methods to treat cancer having a deficiency in ARID1 A and/or mismatch repair deficiency, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with immunotherapies.

A nucleic acid molecule encoding a fusion protein composed of an inducible multimerization moiety at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for exogenous stimulus/G3BP-mediated stress granule formation. Further disclosed are chemical or light inducible multimerization proteins or protein domains that can be used for the nucleic acid molecule production, and a method of inducing stress granule formation in a cell comprising expressing the nucleic acid molecule.

The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

Multivalent binding compositions including a particle-nucleotide conjugate having a plurality of copies of a nucleotide attached to the particle are described. The multivalent binding compositions allow one to localize detectable signals to active regions of biochemical interaction, e.g., sites of protein-protein interaction, protein-nucleic acid interaction, nucleic acid hybridization, or enzymatic reaction, and can be used to identify sites of base incorporation in elongating nucleic acid chains during polymerase reactions and to provide improved base discrimination for sequencing and array based applications.

Multivalent binding compositions including a particle-nucleotide conjugate having a plurality of copies of a nucleotide attached to the particle are described. The multivalent binding compositions allow one to localize detectable signals to active regions of biochemical interaction, e.g., sites of protein-protein interaction, protein-nucleic acid interaction, nucleic acid hybridization, or enzymatic reaction, and can be used to identify sites of base incorporation in elongating nucleic acid chains during polymerase reactions and to provide improved base discrimination for sequencing and array based applications.

A peptide is disclosed that has an amino acid sequence selected from X.sub.1-X.sub.2-X.sub.3-Gln-Leu-Met-Leu-Cys-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 3), X.sub.1-X.sub.2-X.sub.3-Gln-X.sub.7-Met-X.sub.10 -Cys-Val-X.sub.11-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5), Leu-Cys-Val-Leu-Asp-Tyr-Phe (SEQ ID NO: 6), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 10), Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11 (SEQ ID NO: 11), Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu (SEQ ID NO: 12), X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu (SEQ ID NO: 13), Asp-Leu-Val-Ile-Ser-Phe-Gln-Leu-Met-Leu-Cys-Val-Leu-Asp-Tyr-Phe-Ile-Lys (SEQ ID NO: 14) and retro-inverso peptides thereof. The peptides disclosed herein may be used to treat liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.

The invention relates to modified helicases with reduced unbinding from polynucleotides. The helicases can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

Testing peptides in in vitro models of neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Frontotemporal dementia, Amyotrophic lateral sclerosis, to evaluate systems and methods of treatment therefore.